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Abstract Purpose: In breast cancer, the presence of estrogen receptor a (ER) denotes a better prognosis and response to antiestrogen therapy. Lack of ERa correlates with overexpression of epidermal growth factor receptor or c-erbB-2. We have shown that hyperactivation of mitogen-activated protein kinase (MAPK) directly represses ERa expression in a reversible manner. In this study, we determine if inhibition of MAPK in established ERa --breast cancer cell lines and tumors results in reexpression of ERa, and further, if reexpression of ERa in these ERa --tumors and cell lines could restore antiestrogen responses. Experimental Design: Established ERa --breast cancer cell lines, ERa --breast tumors, and tumor cell cultures obtained from ERa --tumors were used in this study. Inhibition of hyperactive MAPK was accomplished via the MAPK/ERK kinase 1/2 inhibitor U0126 or via upstream inhibition with Iressa or Herceptin.Western blotting or reverse transcription-PCR for ERa was used to assess the reexpression of ERa in cells treated with U0126. Growth assays with WST-1were done to assess restoration of antiestrogen sensitivity in these cells.
Results: Inhibition of MAPK activity in ERa
--breast cancer cell lines results in reexpression of ERa; upstream inhibition via targeting epidermal growth factor receptor or c-erbB-2 is equally effective. Importantly, this reexpressed ERa can now mediate an antiestrogen response in a subset of these ERa --breast cancer cell lines. Treatment of ERa --tumor specimens with MAPK inhibitors results in restoration of ERa mRNA, and similarly in epithelial cultures from ERa --tumors, MAPK inhibition restores both ERa protein and antiestrogen response. Conclusions:These data show both the possibility of restoring ERa expression and antiestrogen responses in ERa --breast cancer and suggest that there exist ERa --breast cancer patients who would benefit from a combined MAPK inhibition/hormonal therapy.
Breast cancer patients with tumors that do not express estrogen receptors (ERa) have a very poor prognosis. The presence of ERa not only confers increased disease-free survival and overall survival but, more importantly, also predicts for response to hormonal therapies such as tamoxifen (1 -4) . ERa --breast cancers, which account for approximately one third of all invasive breast cancers, are associated with a more aggressive and metastatic phenotype and overexpression of tyrosine kinase receptors such as the epidermal growth factor receptor (EGFR) or c-erbB-2, with resultant hyperactivation of downstream signaling pathways including p42/44 mitogen-activated protein kinase (MAPK; refs. 5 -15) . Several questions exist about the biological pathways and alterations involved in determining ERa expression and its regulation during breast cancer evolution. Current evidence suggests that most ERa --breast cancers arise from ERa + cells that stop expressing the receptor (16) . Proposed mechanisms for the origin of ERa --breast cancers include that of pressures being exerted on ERa + cells by hyperactivation of MAPK due to overexpression of EGFR or c-erbB-2 (17), estrogen withdrawal (18, 19) , or hypoxia (20, 21) , as well as more permanent epigenetic alterations such as methylation of CpG islands in the ERa gene promoter region (22, 23) . Using engineered cell line models of up-regulated growth factor signaling through EGFR, erbB-2, Raf, and MAPK/ERK kinase, we have previously shown that hyperactivation of MAPK directly represses ERa expression and, importantly, that this repression is reversible via inhibition of MAPK (17, 24) . Recently, we have established a MAPK gene profile that accurately distinguishes ERa --from ERa + breast cancer, further showing the link between hyperactive MAPK and the ERa --phenotype (25) . In this study, we have investigated the likelihood of reversing the ERa --phenotype and restoring response to antiestrogens in established ERa --breast cancer lines and in ERa --tumor specimens. The hypothesis that we explore here is that abrogation of the MAPK pathway by either direct inhibition of hyperactivated MAPK or upstream inhibition of overexpressed growth factor receptor (EGFR and/or erbB-2) signaling will result in reexpression of ERa and, thus, restoration of estrogendependence and antiestrogen sensitivity in a subset of ERa --breast cancers.
Materials and Methods
Drugs. U0126 was from Upstate and Herceptin (trastuzumab) was from Genentech. DMSO and 17h-estradiol (E 2 ) were from Sigma. (Z)-4-Hydroxy-tamoxifen was from Calbiochem (EMD Biosciences) and ICI 182,780 was from Tocris Bioscience. Iressa was from AstraZeneca.
Cell lines. Cells were incubated in a 37jC, 5% CO 2 forced-air humidified incubator. SUM 149 and SUM 229 cells were grown in F-12 Nutrient Mixture (Ham) with 5% fetal bovine serum, 10 nmol/L insulin, 5 Ag/mL gentamicin (all Life Technologies, Inc./Invitrogen), 0.5 Ag/mL fungizone (Cambrex), and 1 Ag/mL hydrocortisone (Sigma). SUM 190 cells were grown in F-12 Nutrient Mixture (Ham) but without serum and with the following additions: 5 mmol/L ethanolamine, 10 mmol/L HEPES, 0.5 g/L albumin bovine serum fraction V, 10 nmol/L T3 (as 3,3 ¶,5-triiodo-L-thyronine sodium salt; all from Sigma), 5 Ag/mL transferrin, and 50 Amol/L selenium (Life Technologies). (ca)erbB-2-MCF-7 cells were grown in phenol red -free modified IMEM with L-glutamine, without gentamicin sulfate (Life Technologies), with 10% charcoal-stripped calf serum (Valley Biomedical).
Gel electrophoresis and Western blotting. Whole-cell protein lysates were prepared from cells grown to f80% confluence using Gold Lysis Buffer [20 mmol/L Tris (pH 7.9), 137 mmol/L NaCl, 5 mmol/L EDTA, 10% glycerol, 1% Triton X-100, supplemented with 77 Ag/mL aprotinin, 47 Ag/mL leupeptin, 250 Ag/mL pefabloc SC, 1 Ag/mL pepstatin, and 184 Ag/mL sodium orthovanadate]. Protein concentrations were obtained using the BCA Protein Assay Kit (Pierce). Protein was denatured in Laemmli sample buffer (Bio-Rad), supplemented with 2-mercaptoethanol, by boiling for 3 min followed by quick chilling on ice. The denatured protein was loaded on 7.5% or 10% Tris-glycine PAGEr Gold Precast gels (Cambrex) and electrophoresed in 1Â Tris-glycine-SDS buffer ( . Secondary antibody, diluted in blocking buffer, was added for 1 h at room temperature. The following secondary antibodies were used: enhanced chemiluminescence antimouse IgG horseradish peroxidase -linked whole antibody (from sheep; Amersham) and enhanced chemiluminescence antirabbit IgG horseradish peroxidase -linked whole antibody (from donkey; Amersham). Membranes were washed with TBS-T. Chemiluminescent detection was accomplished using SuperSignal West Pico substrate (Pierce) following the manufacturer's protocol. Following detection, membranes were stripped with Restore Western Blot Stripping buffer (Pierce) for 15 min at room temperature, then washed in TBS-T. The stripped membranes were then probed for actin to verify even loading. Actin (I-19) horseradish peroxidaseconjugated antibody (Santa Cruz Biotechnology) was used following the above protocol, with the exclusion of the secondary antibody step.
Growth assays. Twenty-four hours before adding the treatments, 1,000 to 3,000 cells (depending on cell line) were plated in each well of a 96-well tissue culture plate in 100-AL medium. Treatments were made at 2Â concentration in medium and 100 AL were added to the preplated cells. Cells were incubated for 0 (in growth medium only), 2, 4 or 6 days. SUM cell lines were refed and re-treated every 24 to 48 h (depending on cell line and dose of inhibitor). At each time point, 1/10 volume of Cell Proliferation Reagent WST-1 (Roche Applied Science) was added to each well and the plates were incubated at 37jC for 60 to 90 min (consistent time per cell line, but differing times for each cell line). Absorbances were read at 450/630 nm on a microplate reader [Dynex Revelation (Dynex Technologies) or Bio-Rad Benchmark Plus].
Ex vivo tumors, tumor dissociation, and tumor cell cultures. Breast tumors were procured from surgical patients by the Tissue Procurement Core of the University of Michigan Comprehensive Cancer Center, following the Institutional Review Board protocol. The freshly procured tissue was used immediately for experiments or dissociation. For experiments using tissue chunks (ex vivo tumors), tumor was minced into small pieces and randomly divided into treatment groups. Each group was cultured in a 100-mm TC plate containing phenol red -free, modified IMEM with L-glutamine, without gentamicin sulfate (Life Technologies/Invitrogen), with 10% charcoal-stripped calf serum (Valley Biomedical), 50 Ag/mL gentamicin, and the appropriate treatment. Treatments consisted of vehicle control (DMSO) or 10 Amol/L U0126. Samples were incubated at 37jC, 5% CO 2 for 20 h before harvest for RNA (except for tumor no. 15, which was incubated for 48 h). To create cell cultures, tumors were minced into small pieces with a scalpel and dissociated in serum-free modified IMEM, with L-glutamine, without gentamicin sulfate and phenol red, supplemented with 300 units/mL collagenase type 3, 100 units/mL hyaluronidase (both from Worthington Biochemical), 2% bovine serum albumin fraction V, and 5 Ag/mL recombinant human insulin (Sigma), at 37jC, 5% CO 2 with gentle agitation for 5 to 16 h until the majority of tissue was digested. The dissociated cells were centrifuged at 100 Â g for 5 min to pellet the epithelial cells. + designation by pathology), and DT16 (ER --/PR --/H2N --designation by pathology). DT5, DT13, and DT16 were also grown in the same media but minus phenol red and insulin and with 10% charcoalstripped calf serum.
Real-time PCR. Before RNA extraction, tumor chunks were stored in RNAlater (Ambion). Tissue chunks were homogenized in TRIzol reagent (Life Technologies/Invitrogen) with a glass dounce homogenizer. RNA was extracted according to the TRIzol manufacturer's protocol. RNA from cell lines was also extracted with TRIzol reagent per manufacturer's protocol. RNA was DNase treated using TURBO DNase (RNase-Free; Ambion) following the manufacturer's protocol. The DNase-treated RNA was then subjected to reverse transcription using TaqMan reverse transcription reagents (Applied Biosystems). RNA was denatured at 65jC for 5 min followed by a quick chill on ice before addition to the reverse transcription reaction. Plus reverse transcription reactions were carried out in a final volume of 10 AL with 0.1 Ag RNA, 1Â reverse transcription buffer, 5.5 mmol/L MgCl 2 , 500 Amol/L of each deoxynucleotide triphosphate, 2.5 Amol/L random hexamers, 0.4 units/AL RNase inhibitor, and 3.125 units/AL MultiScribe reverse transcriptase. Minus reverse transcription reactions were carried out in the same manner as for plus reverse transcription reactions, but MultiScribe reverse transcriptase was omitted. The plus and minus reverse transcription reactions were incubated at 25jC for 10 min, 37jC for 60 min, 95jC for 5 min, followed by a 4jC hold in a thermocycler. Real-time PCR was carried out to determine relative quantification Statistical analysis. To determine if differences in growth assays between different hormone treatments were significant, a two-tailed, type 1 Student's t test was done with n = 5 for all cell treatment groups. The type 1 test was chosen because in each growth assay, it was different treatments of the same cells being compared and not different cell types being compared. In each assay, U0126 + tam was compared with U0126 alone and, similarly, U0126 + ICI 182,780 was compared with U0126 alone. For DT16 cells in Fig. 5 , the additional comparisons of U0126 + tam + E 2 with U0126 + tam and U0126 + ICI 182,780 + E 2 with U0126 + ICI 182,780 were done. For coMCF-7 cells (in Fig. 2) , tam was compared with control and ICI 182,780 was compared with control. In each case, a P value is indicated in the figure.
Results

Restoration of ERa expression in ERa
--breast cancer cell lines via direct MAPK inhibition or via targeted inhibition of EGFR and c-erbB-2. We have previously shown the mechanistic link between hyperactivation of MAPK and down-regulation of ERa expression using MCF-7 cell lines stably overexpressing constitutively active Raf-1, constitutively active MAPK/ERK kinase (MEK), constitutively active c-erbB-2, or ligand-activatable (i.e., +EGF) EGFR as models of overexpressed growth factor signaling. The four engineered cell lines, referred to as (ca)Raf, (ca)MEK, (ca)erbB-2, and EGFR + EGF, all show hyperactivation of MAPK, estrogen-independent growth, and loss of ERa expression (17) . Importantly, inhibition of this hyperactive MAPK restored not only the expression but also the transcriptional function of ERa (17, 24) .
We have now extended these studies to established ERa --breast cancer cell lines. Using three ERa --SUM breast cancer cell lines [SUM 229, which overexpresses EGFR; SUM 190, which overexpresses both EGFR and erbB-2; and SUM 149, which models inflammatory breast cancer and has very high levels of RhoC leading to hyperactivation of nuclear factor nB (NF-nB) in addition to EGFR overexpression], we assessed whether inhibition of MAPK activity could result in restoration of ERa expression. In fact, inhibition of MAPK activity via the pharmacologic MAPK/ERK kinase inhibitor U0126 resulted in significant levels of ERa expression in each of the three cell lines (Fig. 1A-C) . In Fig. 1A , the relative ERa expression levels of both coMCF-7 cells (which express f100-150 fmol/mg protein) and coMCF-7/lt-E 2 cells (coMCF-7 grown long-term in estrogen-depleted media; these cells express f400 fmol/mg protein) are shown for comparison. ERa reexpression was sustained over the 24-h time period in which U0126 was effective in inhibiting the MAPK activity of each of these cell lines. Upstream inhibition of MAPK via inhibition of the overexpressed EGFR (with Iressa in SUM 190 cells) or erbB-2 (with Herceptin in our constitutively active erbB-2 MCF-7 line) is also effective in restoring ERa expression (Fig. 1D) . We also assessed the effects of MAPK inhibition on the expression of two other factors that could be involved in estrogen responses in breast cancer cells, ERh and GPR30. None of these cell lines exhibited appreciable expression of ERh, nor did MAPK inhibition have any effect on this expression. All the cell lines, on the other hand, expressed GPR30, but similar to ERh, MAPK inhibition in these cells had no effect on the GPR30 expression (data not shown).
ERa reexpression restores responses to the antiestrogens tamoxifen and Faslodex. To assess the ability of this reexpressed ERa to restore antiestrogen responsiveness, SUM 229 cells were analyzed in 6-day WST-1 growth assays. The protein results shown in Fig. 1A were achieved with 10 Amol/L U0126; however, this dose used every 24 h was extremely growth inhibitory in SUM 229 cells. Therefore, we carried out a dose response assay to determine a dose that would not, on its own, inhibit growth so that we could observe a tamoxifen or Faslodex response if there was one. U0126 at 1 Amol/L was the maximum tolerated daily dose for these cells, so this dose was then assessed for its ability to restore ERa expression. Whereas 1 Amol/L U0126 did not result in the same large increase in ERa expression that 10 Amol/L did, it was still effective in restoring some ERa expression in SUM 229 cells (Fig. 2A) . Growth assays were then carried out where the effects of 4-hydroxy-tamoxifen and the pure antiestrogen ICI 182,780 (Faslodex) at 10 --7 mol/L alone, 1 Amol/L U0126 alone, or the combination of 4-hydroxy-tamoxifen or ICI 182,780 and U0126 on cell proliferation were assessed by a WST-1 assay at 6 days. For comparison, the growth-inhibitory effects of both 4-hydroxy-tamoxifen and ICI 182,780 at 6 days on ERa + coMCF-7 is shown in Fig. 2B (left) . As can be seen in Fig. 2B (right), 1 Amol/L U016, although not having growth-inhibitory effects on its own in SUM 229 cells, restored the growth-inhibitory effects of both 4-hydroxy-tamoxifen and ICI 182,780. Estrogen addition to ICI 182,780 and U0126 partially reversed the antiestrogen inhibition, indicating that this is a specific ER-mediated effect; however, estrogen by itself did not further induce growth presumably because these cells were growing at their maximum rate and this dose of U0126 was not inhibiting their growth. When a slightly higher dose of U0126 was used to induce a modest growth suppression, then an estrogen dependence effect on growth can also be observed (data not shown). These data suggest that reexpressed ERa, on inhibition of MAPK activity, is capable of mediating the growth-inhibitory effects of antiestrogens in at least some ERa --breast cancers. SUM 149 cells, on the other hand, were extremely resistant to the growth-inhibitory effects of U0126 although MAPK activity was inhibited. In this cell line in which 10 Amol/L U0126 resulted in a significant increase in ERa expression (Fig. 1A) , this reexpressed ERa could not restore the growth-inhibitory effects of antiestrogens (Fig. 2C) . This could be due to the hyperactivation of NF-nB exhibited by these cells, a wellestablished inducer of antiestrogen resistance (28 -30) . These two cell lines thus serve as examples of two different subsets of ERa --breast cancers: those in which EGFR/erbB-2 -driven MAPK plays a role in cell proliferation, and thus the concomitant inhibition of MAPK and restoration of ERa expression restores ERa-driven growth pathways and antiestrogen sensitivity, and those in which pathways/factors other than growth factor receptor/MAPK drive growth, and thus while inhibition of MAPK restores ERa expression, these other pathways/factors bypass ERa and maintain the antiestrogen resistant phenotype.
Breast cancer cell lines exhibiting a basal phenotype do not exhibit MAPK-dependent reexpression of ERa. We hypothesized that a third subset of ERa --breast cancers would exist: those in which inhibition of MAPK would not result in reexpression of ERa. It is well established that a subset of ERa --breast cancers exhibit hypermethylation of the ERa promoter resulting in the permanent repression of ERa (23, 31, 32) , and thus MAPK inhibition alone would not be expected to restore ERa expression in this case. More recently, breast tumors have been defined as having luminal cell properties or basal cell properties, with the basal cell phenotype correlating with lack of ERa expression, in some cases with BRCA mutation and in many cases with EGFR overexpression (33 -35) . We therefore examined two ERa --breast cancer cell lines (SUM 102 and SUM 159) that have been shown by microarray analyses to display the basal phenotype (36) to further analyze the ability of MAPK inhibition to restore ERa expression. Whereas both cell lines exhibit hyperactive MAPK and U0126 is able to effectively inhibit this MAPK activity, no restoration of ERa expression could be observed in these cells (Fig. 3) . These two cell lines, in fact, turn out to exhibit hypermethylation of the ERa promoter (data not shown). These data suggest that an additional mechanism, hypermethylation of the ERa promoter, operates to repress ERa expression in at least two cell lines exhibiting a basal phenotype such that MAPK inhibition alone is not sufficient to restore ERa expression.
MAPK inhibition of ERa --breast tumors ex vivo results in reexpression of ERa mRNA. To extend these data to more clinically relevant models, we have been obtaining specimens of ERa --tumors from the tissue procurement core. We have assessed specimens from 10 ERa --tumors. On receipt, tumors were minced and divided randomly into tissue culture dishes containing estrogen-depleted medium supplemented with 10 Amol/L U0126 or vehicle control (DMSO). The minced tumor specimens in medium plus or minus U0126 were incubated at 37jC, 5% CO 2 for 20 h. RNA was prepared from all treatment groups and analyzed for ERa mRNA level by real-time PCR. Of the 10 tumors, 6 displayed increased ERa mRNA levels after treatment with U0126 (Fig. 4A) .
ERa reexpression upon MAPK inhibition of dissociated tumor cells from ERa --breast tumors. To ascertain that the reexpressed ERa mRNA exhibited by ERa --tumors ex vivo corresponded to reexpression of ERa protein in tumor cells, we have established cultures from breast tumors acquired from the tissue procurement core. These cultures have been propagated over many passages, and the cell culture established from an ERa + tumor displays high expression of ERa whereas the cell culture from an ERa --tumor does not (Fig. 4B) . Similarly, the cell culture from the ERa --tumor exhibits significant hyperactivation of MAPK whereas the cell culture from the ERa + tumor has relatively low basal MAPK activation, similar to control MCF-7 cells.
Treatment of three of these ERa --cell cultures with 10 Amol/L U0126 does result in inhibition of MAPK activity: for DT5, this occurs at 1 and 4 h, but by 8 h, MAPK activity is returning and is almost back to basal levels by 24 h (Fig. 4C) ; for DT13 and DT16, this also occurs by 1 h and is sustained through 8 h with modest return of MAPK activity occurring by 24 h (Fig. 4C,  DT13 ; data not shown). In all three ERa --cell cultures, this inhibition of MAPK activity (even the relatively short inhibition in DT5) is sufficient to restore ERa expression in these cells (Fig. 4C) . In DT13 and DT16, in which the MAPK inhibition is mostly sustained through 24 h, ERa levels are also sustained through 24 h, but in DT5, ERa levels increase through 8 h and then have dropped back down by 24 h when the MAPK activity is almost fully restored. Re-treatment of these cells with U0126 every 8 h for a 24-h period results in maintenance of the ERa levels observed with 8 h of MAPK inhibition, showing that ERa expression can be maintained for the duration of MAPK inhibition (data not shown). In DT13, which overexpresses ErbB-2, Herceptin is also effective in restoring ERa expression (Fig. 4D) although the inhibition of MAPK by Herceptin occurs early and does not last much beyond 4 h. Similar to the SUM breast cancer cell lines, these DTs exhibited no significant expression of ERh but did express GPR30, and MAPK inhibition had no effect on these expression profiles (data not shown).
We next assessed whether this reexpressed ERa was transcriptionally active by assessing the ability of U0126-mediated restoration of ERa to result in increased expression of the estrogen inducible gene GREB1. DT13 and DT16 were treated with U0126 for 24 h or for 24 h in the presence of 10 nmol/L E 2 for the last 20 h of U0126 treatment (Fig. 4E) . In both cell cultures, the return of ERa expression at 24 h of U0126 treatment results in slight increases in GREB1 expression, whereas estrogen treatment along with U0126 is able to further induce the expression of GREB 1.
ERa reexpression in tumor cell cultures restores responses to estrogen and the antiestrogens tamoxifen and Faslodex. Finally, the ability of restored ERa to mediate an antiestrogen response in these ERa --cell cultures from tumors was assessed in DT16 cells in a 6-day growth assay in which cells were treated with 10 Amol/L U0126 every 48 h. As seen with the established ERa --cell lines, in these dissociated ERa --tumor cells, reexpression of ERa on inhibition of MAPK does restore responses to antiestrogens (Fig. 5) . These antiestrogen responses are specific because estrogen at 10 --8 mol/L E 2 is able to partially reverse the 4-hydroxy-tamoxifen and ICI 182,780 effects.
Discussion
In this study, we have shown the ability to reexpress ERa in ERa --breast cancer cells via the inhibition of hyperactive MAPK resulting from overexpression of EGFR or erbB-2 in both established ERa --breast cancer cell lines and ERa --tumors. This reexpression of ERa can be achieved via either direct inhibition of MAPK or inhibition of the upstream growth factor receptor (EGFR or erbB-2) that is driving its hyperactivation. Furthermore, we have established, for the first time, that the restoration of ERa expression is sufficient to induce antiestrogen responses in a subset of these ERa --breast cancer cells.
The reexpression of ERa in established ERa --breast cancer cell lines has only been previously shown via inhibition of DNA methylation or histone deacetylation in those cell lines in which the ERa promoter has been shown to be methylated (23, 31, 37) . The methylation of ERa promoter is presumably a means of permanent repression secondary to some other down-regulating event. The down-regulation of ERa expression by hyperactive MAPK is a more direct mechanism and is dynamic and reversible (i.e., the down-regulation is reversed by the inhibition of MAPK activity and occurs again shortly after return of MAPK activity). And as we found with the two cell lines in which the ERa promoter turned out to be hypermethylated, despite the very high levels of MAPK exhibited by these cells and the effectiveness of U0126 in inhibiting MAPK, ERa expression could not be restored. Our data indicate that in addition to hypermethylation of the ERa promoter, hyperactivation of MAPK resulting from overexpression of EGFR or erbB-2 can also be directly responsible for the lack of ERa expression in ERa --tumors. Importantly, this MAPK-meditated down-regulation of ERa expression can be targeted to result in reexpression of ERa. In fact, it has recently been shown that in a small study of 10 ERa --/erbB-2 + patients treated for various lengths of time with Herceptin, 3 patients reexpressed ERa (38) . A more recent study by Massarweh et al. suggests that this mechanism can also be exploited in ERa + /erbB-2 + tumors that lose ERa expression during treatment. They found that resistance to estrogen deprivation/fulvestrant in an ERa + / erbB-2 + MCF-7 xenograft model was accompanied by upregulation of MAPK activity and loss of ERa expression, and subsequent cotreatment with Iressa resulted in inhibition of MAPK activity and increased ERa expression (39) .
Regardless of the different potential mechanisms for downregulating/restoring ERa expression, the reexpressed ERa must not only be functional on reexpression (i.e., induce the regulation of estrogen-responsive genes) but must also be able to regulate growth in response to estrogen/antiestrogens to be clinically relevant. In studies wherein demethylation of the ERa promoter or use of histone deacetylase inhibitors restored ERa expression, this ERa was functional in that it could regulate ERE-luciferase activity as well as the expression of specific estrogen-regulated genes such as the progesterone receptor (37, 40, 41) . In addition, in both our previous studies in our hyperactive MAPK cell line models, wherein reexpression of ERa on inhibition of MAPK also restored ERa transcriptional activity (17, 24) , and our current study, wherein the reexpressed ERa in both DT13 and DT16 was able to induce the expression of GREB1 (Fig. 4E) , an estrogen-induced gene, we show the restoration of ERa function. Importantly, for clinical applicability, the ability of the reexpressed ERa on MAPK inhibition to mediate the growth inhibition of antiestrogens in both established ERa --breast cancer cell lines and dissociated tumor cell cultures shows clearly for the first time the potential for a novel therapeutic strategy for ERa --breast cancer. In these studies, two different cell line types were observed. In the SUM 229 cell line, which was quite sensitive to MAPK inhibition in terms of growth inhibition, restoration of ERa expression correlated with restoration of response to both 4-hydroxytamoxifen and ICI 182,780 (fulvestrant, Faslodex); however, in the SUM 149 cell line, which also exhibits hyperactivation of NF-nB and RhoC overexpression (42 -44) , the reexpressed ERa was not able to restore responses to either antiestrogen. This is most likely due to the hyperactivation of NF-nB, which is known to result in antiestrogen resistance in breast cancer cells (28 -30, 45) . Thus, although the MAPK repression of ERa mechanism is operative in these cells and can thus be targeted to allow for reexpression of ERa, the cells have additional cell signaling alterations that allow them to bypass ERa and remain antiestrogen resistant although now ERa + . Indeed, these cells were very resistant to growth inhibition induced by MAPK inhibition whereas even modest inhibition of NF-nB significantly affected their proliferation (data not shown). Not surprisingly, the level of reexpressed ERa necessary to restore antiestrogen effects does not need to be as high as that observed in MCF-7 cells, f100 to 150 fmol/mg protein (Figs. 2 and 4 ). There are several established ERa + breast cancer cell lines with varying ERa levels, all lower than that of MCF-7, which are estrogen dependent and exhibit full estrogen responsiveness, such as T47D, ZR75.1, and BT474.
Together, these data are suggestive of a number of important possibilities for the treatment of ERa --breast cancer (Fig. 6 ). First, it is clear that in the large majority of ERa --breast tumors, hyperactivation of MAPK by upstream overexpressed/hyperactive EGFR or c-erbB-2 represses ERa expression, and thus can be targeted to allow for reexpression of ERa. This targeting can be at the level of MAPK activity itself or via upstream inhibition of EGFR/erbB-2 signaling. In the subset of ERa --tumors exhibiting hypermethylation of the ERa promoter, such targeting alone is not successful in restoring ERa expression but would most likely be necessary to maintain ERa expression after demethylation of the promoter because these tumors also exhibit high MAPK activity. Importantly, restoration of ERa expression simultaneously restores estrogen/antiestrogen responses in those ERa --tumors in which MAPK signaling seems to be the predominant mediator of proliferation. However, where alternative signaling pathways, such as NF-nB, seem to be the predominant proliferation mediators, concomitant inhibition of the alternate signaling pathway would be necessary to allow the restored ERa to mediate antiestrogen responses. Furthermore, in those tumors exhibiting hypermethylation of the ERa promoter, in which it has recently been shown that inhibitors of histone deacetylases are equally effective in relieving the repression of ERa transcription (37) , a combination of a histone deacetylase inhibitor and MAPK inhibition may be an effective means of restoring antiestrogen responses. Finally, these data indicate that ERa status, rather than being solely positive or negative, is a dynamic process strongly affected by the signaling environment of breast cancer cells.
